Enesi Pharma Secures Innovate UK Funding to Enable Scalable Aseptic Manufacturing of ImplaVax®-enabled Solid Dose Viral Vector Vaccines

OXFORD, UK – 24 September 2019 – Enesi Pharma (“Enesi”), the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has secured substantial funding from Innovate UK, the UK’s innovation agency, under the Biomedical Catalyst 2019 Round 1: Early and Late Stage Awards Initiative. The award of £870,419 will co-fund a major new £1.24 million project to develop a scalable aseptic manufacturing process for live or live-attenuated viral vectors for use with Enesi’s ImplaVax® needle-free solid dose technology.
 

David Hipkiss, Enesi Pharma CEO, commented:
 

“This substantial grant from Innovate UK will enable us to address a crucial challenge in the development of viral vector vaccines into a viable delivery format and to access the myriad benefits of our unique ImplaVax® needle-free solid dose platform.



“Viral vector vaccines represent a rapidly growing area of interest as they form the foundation of multiple new candidates being developed by many companies to target defined and high-value opportunities in infectious diseases, emergent threat pathogens, allergies and oncology. We have already initiated exploratory studies on two of the most widely used viral vectors in development across the pharmaceutical industry – adenovirus and vaccinia virus – working in collaboration with leading international partners, including the University of Oxford, Sementis and Geovax.



“The Innovate UK grant not only will support the advancement of these programs but crucially its success will pave the way for Enesi to capture future opportunities addressing a wide range of global public health concerns.”